The Vasculitis Foundation, the leading international supporter of research on vasculitis, is pleased to announce a special funding opportunity to fund research on Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg Strauss Syndrome).
EGPA is a rare systemic vasculitis predominantly affecting small-sized vessels. Main clinical characteristics of EGPA include late-onset allergic rhinitis and asthma, increased blood eosinophil count and vasculitis manifestations, some of which can be life-threatening. Mechanisms of the disease are complex and not completely elucidated, but treatment is well standardized, and the majority of patients respond well to therapy.
The award will provide up to $50,000 to support a one-year study to stimulate research that addresses scientific questions related to EGPA. The VF Research Program places a high priority on both clinical and basic scientific research into the cause, prevention, detection, treatment and cure of EGPA.
This is a special funding opportunity and applications will be considered separately from the VF’s Research Program’s annual review cycle of research grant applications.
Letters of Interest: Interested individuals/organizations should submit letters of interest no later than March 1, 2015, containing the following preliminary information:
- Your name, address, phone number, email address and institution.
- A one-paragraph description of your proposed research study.
Application deadline: April 1, 2015
Selection Process: Applications will be reviewed by a panel of VF selected experts in the areas of vasculitis. The review process will occur over a 4-week period (April – May 2015). A single award will be provided by June 2015 to the most meritorious applicant(s) that meets committee objectives.